Literature DB >> 26801672

NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.

Suqing Liu1, Jing Sun1, Bin Cai1, Xiaowei Xi1, Liu Yang1, Zhenbo Zhang1, Youji Feng1, Yunyan Sun2.   

Abstract

NANOG is a key transcription factor that is overexpressed and plays an important role in various cancers. Its overexpression is associated with highly tumorigenic, drug-resistant, and poor prognosis. However, the underlying mechanism of action of NANOG in ovarian cancer remains unclear. Epithelial-mesenchymal transition (EMT), which is a critical process in cancer invasion and metastasis, is also associated with drug resistance. We determined whether NANOG is associated with EMT and chemoresistance in epithelial ovarian cancer cells. NANOG expression was increased in epithelial ovarian cancer cells (HEY and SKOV3) compared with normal epithelial ovarian cells (Moody). Low expression of NANOG increased the expression of E-cadherin and decreased the expression of vimentin, β-catenin, and Snail. Furthermore, the cell migration and invasion abilities were decreased. The multidrug resistance genes MDR-1 and GST-π were also downregulated when NANOG was lowly expressed. The cells that were transfected with the si-NANOG plasmid were more sensitive to cisplatin compared with the cells that were transfected with empty vector. The data demonstrated that Stat3 was correlated with NANOG-mediated EMT and drug resistance. The silencing of Stat3 expression abrogated NANOG-mediated EMT changes and increased the sensitivity of the cells to chemotherapy. These results suggest that NANOG mediates EMT and drug resistance through activation of the Stat3 pathway in epithelial ovarian cancer.

Entities:  

Keywords:  Chemoresistance; EMT; NANOG; Ovarian cancer; Stat3

Mesh:

Substances:

Year:  2016        PMID: 26801672     DOI: 10.1007/s13277-016-4848-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.

Authors:  Yanan Wei; Zhenbo Zhang; Hong Liao; Ling Wu; Xiaomei Wu; Dongmei Zhou; Xiaowei Xi; Yaping Zhu; Youji Feng
Journal:  Oncol Rep       Date:  2011-11-08       Impact factor: 3.906

2.  Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.

Authors:  Juanjuan Shan; Junjie Shen; Limei Liu; Feng Xia; Chuan Xu; Guangjie Duan; Yanmin Xu; Qinghua Ma; Zhi Yang; Qianzhen Zhang; Leina Ma; Jia Liu; Senlin Xu; Xiaochu Yan; Ping Bie; Youhong Cui; Xiu-wu Bian; Cheng Qian
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

3.  Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.

Authors:  Yongmiao Pan; Jie Jiao; Caiyun Zhou; Qi Cheng; Yuting Hu; Huaizeng Chen
Journal:  Pathobiology       Date:  2011-01-24       Impact factor: 4.342

4.  Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.

Authors:  Shih-Hwa Chiou; Mong-Lien Wang; Yu-Ting Chou; Chi-Jen Chen; Chun-Fu Hong; Wang-Ju Hsieh; Hsin-Tzu Chang; Ying-Shan Chen; Tzu-Wei Lin; Han-Sui Hsu; Cheng-Wen Wu
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway.

Authors:  Chun Sun; Lu Sun; Kai Jiang; Dong-Mei Gao; Xiao-Nan Kang; Cun Wang; Shu Zhang; Shan Huang; Xue Qin; Yan Li; Yin-Kun Liu
Journal:  Int J Biochem Cell Biol       Date:  2013-03-07       Impact factor: 5.085

Review 6.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

7.  FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.

Authors:  Wen-Tai Chiu; Yu-Fang Huang; Huei-Yu Tsai; Chien-Chin Chen; Chang-Hwa Chang; Soon-Cen Huang; Keng-Fu Hsu; Cheng-Yang Chou
Journal:  Oncotarget       Date:  2015-02-10

8.  Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.

Authors:  Zhenbo Zhang; Yaping Zhu; Yunli Lai; Xiaomei Wu; Zhengzhong Feng; Yinhua Yu; Robert C Bast; Xiaoping Wan; Xiaowei Xi; Youji Feng
Journal:  Int J Oncol       Date:  2013-08-06       Impact factor: 5.650

9.  Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients.

Authors:  Dan Wang; Ping Lu; Hao Zhang; Minna Luo; Xin Zhang; Xiaofei Wei; Jiyue Gao; Zuowei Zhao; Caigang Liu
Journal:  Oncotarget       Date:  2014-11-15

10.  Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Authors:  E Sanchez-Lopez; E Flashner-Abramson; S Shalapour; Z Zhong; K Taniguchi; A Levitzki; M Karin
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more
  28 in total

1.  Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells.

Authors:  Yuan Li; Shengkai Huang; Yan Li; Weilong Zhang; Kun He; Mei Zhao; Hong Lin; Dongdong Li; Honggang Zhang; Zhaoxu Zheng; Changzhi Huang
Journal:  Tumour Biol       Date:  2016-08-23

2.  Synergistic effect of Tripterygium glycosides and cisplatin on drug-resistant human epithelial ovarian cancer via ILK/GSK3β/Slug signal pathway.

Authors:  Yayuan Yu; Wencheng Liu; Xinlu Zhan; Yanying Zhong; Ying Feng; Qing Cao; Buzhen Tan
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 3.  Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.

Authors:  Mohammad Aslam Khan; Kunwar Somesh Vikramdeo; Sarabjeet Kour Sudan; Seema Singh; Annelise Wilhite; Santanu Dasgupta; Rodney Paul Rocconi; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2021-08-18       Impact factor: 15.707

4.  STAT3 mediates RCP-induced cancer cell invasion through the NF-κB/Slug/MT1-MMP signaling cascade.

Authors:  Su Jin Cho; Bo Young Jeong; Young Soo Song; Chang Gyo Park; Do Yeun Cho; Hoi Young Lee
Journal:  Arch Pharm Res       Date:  2022-07-09       Impact factor: 6.010

Review 5.  The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

Authors:  Michael F Emmons; Fernanda Faião-Flores; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2016-06-25       Impact factor: 5.858

Review 6.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

Review 7.  The molecular mechanisms of chemoresistance in cancers.

Authors:  Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2017-07-06

8.  Intermittent calorie restriction enhances epithelial-mesenchymal transition through the alteration of energy metabolism in a mouse tumor model.

Authors:  Osamu Kusuoka; Rina Fujiwara-Tani; Chie Nakashima; Kiyomu Fujii; Hitoshi Ohmori; Takuya Mori; Shingo Kishi; Yoshihiro Miyagawa; Kei Goto; Isao Kawahara; Hiroki Kuniyasu
Journal:  Int J Oncol       Date:  2017-12-18       Impact factor: 5.650

9.  Transgenic overexpression of NanogP8 in the mouse prostate is insufficient to initiate tumorigenesis but weakly promotes tumor development in the Hi-Myc mouse model.

Authors:  Bigang Liu; Shuai Gong; Qiuhui Li; Xin Chen; John Moore; Mahipal V Suraneni; Mark D Badeaux; Collene R Jeter; Jianjun Shen; Rashid Mehmood; Qingxia Fan; Dean G Tang
Journal:  Oncotarget       Date:  2017-04-18

10.  A Novel Role For Nanog As An Early Cancer Risk Marker In Patients With Laryngeal Precancerous Lesions.

Authors:  Juan P Rodrigo; M Ángeles Villaronga; Sofía T Menéndez; Francisco Hermida-Prado; Miquel Quer; Isabel Vilaseca; Eva Allonca; Daniel Pedregal Mallo; Aurora Astudillo; Juana M García-Pedrero
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.